8-K current report · filed Nov 16, 2026

Arcturus Therapeutics Holdings Inc. (ARCT) 8-K Current Report: November 16, 2026

Item 1.01Item 3.02Item 7.01Item EX-99.1ARCT overview

Short answer

Arcturus Therapeutics Holdings Inc. (ARCT) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). $50.0M equity sale to Meiji at an 80% premium, providing non-dilutive-to-cash funding but issuing 2,466,395 shares.

Arcturus Therapeutics Holdings Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $50.0M equity sale to Meiji at an 80% premium, providing non-dilutive-to-cash funding but issuing 2,466,395 shares
  • Meiji’s ARCT-154 license covers an undisclosed therapeutic area, with Meiji funding development and commercialization
  • Potential Japan pandemic-preparedness license remains non-binding, creating strategic upside without a committed transaction
  • Failure to sign the definitive Japan license by May 31, 2027 triggers an approximately $11.1M refund obligation
  • Meiji faces a 365-day transfer lockup and 9.9% ownership cap, limiting near-term selling and control accumulation risk

Item 3.02 · Unregistered Sales of Equity Securities

  • Unregistered share issuance under Section 4(a)(2), indicating a private placement exempt from Securities Act registration
  • Shares subject to resale restrictions until registration or another exemption applies
  • Investors should review Item 1.01 for purchase price, share count, proceeds, and registration-rights terms

Item 7.01 · Regulation FD Disclosure

  • Press release announces transactions with Meiji, signaling a potentially material strategic or commercial development
  • Exhibit 99.1 contains the transaction terms investors need to assess financial and operational impact

Item EX-99.1 · Exhibit EX-99.1

  • $50M Meiji equity investment at $20.27 per share, an 80% premium and 7.9% post-transaction ownership
  • Proceeds earmarked to accelerate ARCT-2601 development for OTC deficiency and clinically validate LUNAR 2.0
  • Expanded collaboration includes an exclusive ARCT-154 license for an undisclosed therapeutic area
  • Japan pandemic-preparedness MOU creates potential future collaboration and licensing revenue, but remains nonbinding
  • Transaction strengthens funding and strategic validation while creating dilution for existing shareholders

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Arcturus Therapeutics Holdings Inc. 8-K filings

Get the next ARCT 8-K as it lands

Follow ARCT for push alerts, or ask the research agent what this filing means.